Oelke M - Search Results

1

Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Gacci M, Carini M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, Maggi M, McVary KT, Kaplan SA, Oelke M, Serni S. Gacci M, et al. Among authors: oelke m. Drugs Aging. 2014 Jun;31(6):425-39. doi: 10.1007/s40266-014-0177-1. Drugs Aging. 2014. PMID: 24811735 Review.

2

Drug-induced urinary incontinence.

Tsakiris P, Oelke M, Michel MC. Tsakiris P, et al. Among authors: oelke m. Drugs Aging. 2008;25(7):541-9. doi: 10.2165/00002512-200825070-00001. Drugs Aging. 2008. PMID: 18582143 Review.

3

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Uckert S, Oelke M. Uckert S, et al. Among authors: oelke m. Br J Clin Pharmacol. 2011 Aug;72(2):197-204. doi: 10.1111/j.1365-2125.2010.03828.x. Br J Clin Pharmacol. 2011. PMID: 21745238 Free PMC article. Review.

4

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Oelke M, et al. Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20. Eur Urol. 2012. PMID: 22297243 Clinical Trial.

5

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, Marberger M, Montorsi F, Novara G, Oelke M, Porst H, Roehrborn C, Stief C, McVary KT. Füllhase C, et al. Among authors: oelke m. Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.01.018. Epub 2013 Jan 25. Eur Urol. 2013. PMID: 23375241 Review.

6

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology. Oelke M, et al. Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Eur Urol. 2013. PMID: 23541338 Review.

7

Phosphodiesterase inhibitors in clinical urology.

Ückert S, Kuczyk MA, Oelke M. Ückert S, et al. Among authors: oelke m. Expert Rev Clin Pharmacol. 2013 May;6(3):323-32. doi: 10.1586/ecp.13.16. Expert Rev Clin Pharmacol. 2013. PMID: 23656343 Review.

8

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L. Porst H, et al. Among authors: oelke m. Urology. 2013 Sep;82(3):667-73. doi: 10.1016/j.urology.2013.05.005. Epub 2013 Jul 19. Urology. 2013. PMID: 23876588 Clinical Trial.

9

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.

Gacci M, Sebastianelli A, Salvi M, Vignozzi L, Corona G, McVary KT, Kaplan SA, Oelke M, Maggi M, Carini M. Gacci M, et al. Among authors: oelke m. Curr Bladder Dysfunct Rep. 2013 Jun;8(2):150-159. doi: 10.1007/s11884-013-0184-9. Curr Bladder Dysfunct Rep. 2013. PMID: 23888186 Free PMC article.

10

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction.

Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M, Oelke M. Gacci M, et al. Among authors: oelke m. Res Rep Urol. 2013 Apr 6;5:99-111. doi: 10.2147/RRU.S31580. Res Rep Urol. 2013. PMID: 24400241 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters